Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland

DelveInsight's "Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Liver Cirrhosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cirrhosis Market Forecast [https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Liver Cirrhosis Market Report:

*
The Liver Cirrhosis market size was valued approximately USD 3,100 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In April 2025, Enrollment has been finalized for the Phase 3 NATiV3 clinical trial (NCT04849728), which is evaluating lanifibranor in individuals with metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis. According to the developer, Inventiva, if the results are favorable, the top-line data from this global study could support regulatory approval submissions for lanifibranor.

*
In March 2025, According to two-year data from the Phase 3 MAESTRO-NAFLD-1 clinical trial (NCT04197479), long-term treatment with Rezdiffra (resmetirom) has been shown to reduce liver scarring in most individuals with compensated cirrhosis-irreversible scarring in a still-functioning liver-caused by metabolic dysfunction-associated steatohepatitis (MASH). This finding was recently revealed by Madrigal Pharmaceuticals, the developer of the therapy.

*
In March 2025, Akero Therapeutics' experimental therapy efruxifermin has shown the ability to reverse compensated cirrhosis-permanent liver scarring with preserved function-in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. These top-line results come from the Phase 2b SYMMETRY clinical trial (NCT05039450) and were described by the company as both "unprecedented" and statistically significant in a recent press release. The findings align with previous Phase 2b HARMONY trial (NCT04767529) data, which demonstrated that efruxifermin reduced liver fibrosis in patients with MASH who had not yet developed cirrhosis.

*
In January 2025, Akero Therapeutics has announced preliminary topline results from week 96 of its Phase IIb SYMMETRY study evaluating efruxifermin (EFX) in adults with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial focused on individuals with the condition.

*
In December 2024, Galectin Therapeutics revealed findings from its global NAVIGATE clinical trial assessing belapectin in individuals with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.

*
In October 2024, PharmaIN Corporation announced that it will present interim findings from its ongoing Phase I clinical trial of PHIN-214, its leading candidate for preventing and treating decompensated cirrhosis.

*
In 2023, the market size for liver cirrhosis in the EU4 and the UK was approximately USD 566 million.

*
In 2023, Germany had the largest market size for liver cirrhosis among EU countries, reaching nearly USD 152 million, while Spain had the smallest, with a market size of approximately USD 77 million.

*
In 2023, the total number of diagnosed prevalent cases of Liver Cirrhosis in the US was around 2,070 thousand, with expectations for growth throughout the forecast period.

*
The US alone has the highest number of diagnosed prevalent cases of liver cirrhosis among the 7MM, followed by the EU4, the UK, and Japan, which contribute 24% and 14% of all liver cirrhosis cases, respectively.

*
The distribution of diagnosed prevalent cases of liver cirrhosis by etiology in Japan revealed that MASH, HCV, HBV, ALD, and PBC accounted for 13%, 45%, 15%, 26%, and 2% of cases, respectively.

*
In 2023, the EU4 and the UK had approximately 830 thousand diagnosed prevalent cases of liver cirrhosis, with Germany reporting the highest number of cases

*
Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others

*
Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others

*
The Liver Cirrhosis epidemiology based on gender analyzed that males are more affected with Liver Cirrhosis than females

*
The Liver Cirrhosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cirrhosis pipeline products will significantly revolutionize the Liver Cirrhosis market dynamics.

Liver Cirrhosis Overview

A late-stage liver condition called liver cirrhosis causes the liver to become irreversibly damaged when good liver tissue is replaced with scar tissue.

Get a Free sample for the Liver Cirrhosis Market Report

https://www.delveinsight.com/report-store/liver-cirrhosis-market [https://www.delveinsight.com/report-store/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Liver Cirrhosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Cirrhosis Epidemiology Segmentation:

The Liver Cirrhosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Liver Cirrhosis

*
Prevalent Cases of Liver Cirrhosis by severity

*
Gender-specific Prevalence of Liver Cirrhosis

*
Diagnosed Cases of Episodic and Chronic Liver Cirrhosis

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ Liver Cirrhosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Liver Cirrhosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cirrhosis market or expected to get launched during the study period. The analysis covers Liver Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Cirrhosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Cirrhosis Therapies and Key Companies

*
Resmetirom: Madrigal Pharmaceuticals Inc.

*
Belapectin: Galectin Therapeutics

*
Efruxifermin: AkeroTherapeutics

*
LPCN 1148: Lipocine Inc

*
IDN-6556: Conatus Pharma

*
NRL972: Norgine

*
Resmetirom: Madrigal Pharma

*
GXHPC1: Gwo Xi Stem Cell Applied Tech

*
GI262570: GlaxoSmithKline

*
Rifaximin: Bausch Health

*
BMS-986263: Bristol-Myers Squibb

*
MNK6106: Mallinckrodt

*
conivaptan: Cumberland Pharma

*
LPCN 1148: Lipocine Inc.

*
INT-747: Intercept Pharma

*
Satavaptan: Sanofi

*
oltipraz: HK inno.N Corporation

*
Obeticholic Acid (OCA): Intercept Pharma

*
IDN-6556: Conatus Pharmaceuticals Inc.

*
Pregabalin: Pfizer

Discover more about therapies set to grab major Liver Cirrhosis market share @ Liver Cirrhosis Treatment Market [https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Liver Cirrhosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others

*
Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others

*
Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies

*
Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Liver Cirrhosis Unmet Needs, KOL's views, Analyst's views, Liver Cirrhosis Market Access and Reimbursement

To know more about Liver Cirrhosis companies working in the treatment market, visit @ Liver Cirrhosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/liver-cirrhosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Liver Cirrhosis Market Report Introduction

2. Executive Summary for Liver Cirrhosis

3. SWOT analysis of Liver Cirrhosis

4. Liver Cirrhosis Patient Share (%) Overview at a Glance

5. Liver Cirrhosis Market Overview at a Glance

6. Liver Cirrhosis Disease Background and Overview

7. Liver Cirrhosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cirrhosis

9. Liver Cirrhosis Current Treatment and Medical Practices

10. Liver Cirrhosis Unmet Needs

11. Liver Cirrhosis Emerging Therapies

12. Liver Cirrhosis Market Outlook

13. Country-Wise Liver Cirrhosis Market Analysis (2020-2034)

14. Liver Cirrhosis Market Access and Reimbursement of Therapies

15. Liver Cirrhosis Market Drivers

16. Liver Cirrhosis Market Barriers

17. Liver Cirrhosis Appendix

18. Liver Cirrhosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-cirrhosis-market-predicted-to-see-upsurge-through-2034-highlights-delveinsight-pfizer-glaxosmithkline-bausch-health-bristolmyers-squibb-mallinckrodt-cumberland]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.